The science behind TTF was pioneered by Dr. Yorum Palti, MD, PhD, Professor Emeritus of Physiology and Biophysics at the Technion – Israel Institute of Technology. More than 15 years ago, Dr. Palti’s groundbreaking research demonstrated the ability of TTF to reduce solid tumors, laying the foundation for a new approach in cancer therapy. Over 500 academic articles have been published since then exploring the science and clinical potential of TTF.​

While the exact mechanism of action continues to be refined, some of the most compelling recent findings come from research led by Dr. Kenneth D. Swanson, PhD, of Harvard Medical School in Boston, Massachusetts.​

Specially tuned TTFs are sent through cancer cells while they’re dividing. These fields interact with charged particles inside the cells—called dipoles—which have a positive charge on one end and a negative charge on the other. As the electric field alternates, it causes these particles to move back and forth, disrupting their normal function and preventing the cancer cells from dividing properly.

Cells that undergo division while exposed to TTF are damaged in the process and exhibit clear signs of cellular distress.

Dr. Kenneth Swanson's full scientific presentation via YouTube: 

Evidence suggests that the stress experienced by cancer cells dividing under TTF triggers an immune response, leading to cell death and contributing to tumor reduction.